The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•25 March 2026•

1 min read

Co-Diagnostics Ships TB Testing Equipment to India for Clinical Trials

Key Facts

1Co-Diagnostics (CODX) has commenced shipments of PCR Pro instruments and TB test kits to its joint venture in India, CoSara.

2The shipment aims to initiate clinical studies aligned with new WHO recommendations for near-point-of-care molecular testing.

Co-Diagnostics, Inc. (CODX) has officially commenced shipping its PCR Pro instruments and tuberculosis (TB) test kits to its Indian joint venture, CoSara Diagnostics. This move is intended to launch clinical studies that align with the latest World Health Organization (WHO) recommendations for near-point-of-care molecular testing. The diagnostic platform utilizes the company's proprietary tongue swab technology, which simplifies the sample collection and preparation process. These trials represent a critical step in the company's efforts to penetrate the Indian healthcare market, which faces a significant TB burden. By adhering to WHO standards, Co-Diagnostics aims to validate its technology for broader international commercialization. Investors view this development as a positive milestone in the company's product pipeline and global expansion strategy.